Research Journal of Pharmacognosy (RJP) editorial policy is in accordance with code of conduct and best practices by COPE. RJP follows the declaration of Helsinki (2013) regarding researches involving humans. For animal or human studies, adequate statistics must be presented and the details of approvals of the research ethical committee including the code and date of approval should be indicated in the experimental section. For clinical trials the registration number (for Iranian authors the IRCT number) should be provided in ethical considerations subsection under material and methods. Please refer to Publication Ethics and malpractice Statement and Ethics in Research before submitting a manuscript.
While preparing the manuscript by authors, every related literature should be cited properly and the manuscripts must be devoid of any kind of plagiarism. The submitted manuscript will be checked for plagiarism by plagiarism check software.
Submitted manuscripts will be subjected to peer-review process by experts in the related fields to evaluate the suitability for publication in RJP. After the review process, the manuscripts will be returned to the authors in case revisions are needed. This process might be repeated if the revision is not satisfactory. By submitting a manuscript to RJP, the authors imply that they are representing an original work that has not been published before and is not considered for publication elsewhere or in any other language. The declarations statement should be signed by each author and uploaded by the corresponding author.
Preparing the cover letter, the authors should clearly mention the type of their manuscripts (original article, short communication,... ), state that the work has not been submitted elsewhere and mention if there is any conflict of interest; also any conflict of interest should be stated before the reference section in the manuscript.
Upon acceptance an agreement should be completed, signed and submitted to the journal.
The publication fee for accepted manuscripts is 12000000 IRR for the Iranian authors and 100 USD for foreign authors. Moreover, 50% discount will be allocated to the corresponding authors who are members of the Iranian Society of Pharmacognosy.
Instruction for authors
Types of contributions
Title page: A title page should also be provided which includes the title, authors’ names and affiliations, authors ORCID ID, with one author clarified as the corresponding author. The full contact information (phone and fax number, e-mail address) should be provided for this person. Also any thanks or appreciations should appear here under acknowledgments section followed by each author contributions under author contributions. Please note that there can be no change in author names, order of appearance or corresponding author after submission.
Main text: The main document should be prepared as a word file arranged in the order of abstract, keywords, introduction, experimental, results and discussion and references. Tables and figures should be provided in the document in their appropriate place and also as separate files with self-explanatory definitions.
All contributions should be started with an abstract . The abstract should include the background, objectives, methods, results and conclusion.
Keywords: 3-5 keywords should be selected. This will help in classifying the manuscript and also the indexing process.
Introduction: States the background of the study. This section should be as brief as possible excluding any irrelevant component.
Material and Methods: Any information regarding the materials and methods used should be included here in a detailed manner.
Results and Discussion: The results of the study and any necessary discussion should be stated in this section and conclusions should be given at the end. In case of biologic studies the results should be provided as IC50 or similar appropriate manner.
References: The accuracy of the references is the responsibility of authors. Citations should be given numerically in the main text (in brackets [ ]) and they should be listed in the reference section. Example:
Alley MC, Scudiero DA, Monkes A, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH, Boyd MR. Feasibility of drug screening with panel of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 1988; 48(3): 589-601.
Giovana DG, Edna S, Milene B, Joice L, Patrícia P, Patrícia A. Effect of rosmarinic and caffeic acids on inflammatory and nociception process in rats. ISRN Pharmacol. 2011; Article ID 451682.
In press manuscripts (maximum 2):
Ozgoli G, Goli M, Moattar F. Comparison of effects of ginger, mefenamic acid, and ibuprofen on pain in women with primary dysmenorrhea. J Altern Complem Med. in press.
Frappier F, Mazier D, Carraz M, Franetich JF, Jossang A, Joyeau R, Rasoanaivo P, inventors; Universite Pierre Et Marie Curie (Paris Vi), Centre National De La Recherche Scientifique, Museum National D'histoire Naturelle, Institut Malgache De Recherche Appliquee, assignee. Alkaloid compounds and their use as anti-malarial drugs. United States patent US 7,943,633. 2011 May 17.
Harborne JB. Phytochemical methods, a guide to modern techniques of plant analysis. 3rd ed. London: Chapman & Hall, 1998.
Author(s) and editor(s)
Breedlove GK, Schorfheide AM. Adolescent pregnancy. 2nd ed. Wieczorek RR, Ed. White Plains (NY): March of Dimes Education Services, 2001.
Organization(s) as author
Royal Adelaide Hospital, University of Adelaide, Department of Clinical Nursing. Compendium of nursing research and practice development, 1999-2000. Adelaide: Adelaide University, 2001.
Chapter in a book
Kumar N, Singh B, Kaul UK, Ahuja PS. Chemical and biological aspects of iridoid bearing plants of temperate region. In: Atta-Ur-Rahman, Ed. Studies in natural products chemistry. Amesterdam: Elsevier, 2005.
Harnden P, Joffe JK, Jones WG. Germ cell tumours V. Proceedings of the 5th Germ Cell Tumour Conference. 2001 Sep 13-15; Leeds, UK.
Senol FS. Pharmacognosic research on some Salvia species growing in Turkey. M.Sc. thesis. Institute of Health Sciences, Gazi University, Ankara, Turkey, 2009.
National Cancer Institute. Leukemia. [Accessed 2017]. Available from: https://www.cancer.gov/types/leukemia/hp.
Tables: Tables should be used just when necessary and not to be a repeat of the results.
Figures: Clear illustrations should be prepared as a separate TIFF or JPEG file with 300 dpi resolution or higher. The legends should be provided at the end of the main text.
Declaration of interest
Any conflict of interest should be noted after the acknowledgments section. If there is no conflict of interest it should be stated as: "The authors declare that there is no conflict of interest."
It should also be mentioned that: "The authors alone are responsible for the content of the paper."
A list of abbreviations (if any) should be found at the end of the manuscript after the reference section.
Every related literature should be cited properly and the manuscripts must be devoid of any kind of plagiarism.
The copyright of the articles published in Research Journal of Pharmacognosy (RJP) retains to the authors and authors are free to reproduce and disseminate their work.
The articles published in Research Journal of Pharmacognosy (RJP) are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The authors are invited to submit their manuscripts through the online submission system: at http://rjpharmacognosy.ir.
The corresponding author of an accepted manuscript will receive proofs which should be returned with corrections within 48 of receipt. It is the responsibility of the corresponding author to ensure that all listed authors of the manuscript agree with the changes made on the proofs.
Enquiries related to the accepted manuscripts and proofs should be directed to:
RJP Editorial Office,
The Iranian Society of Pharmacognosy,
No. 8, Shams Alley, Vali-e-Asr Street,
Postal Code: 1516745811
Phone: +9821 88773521 Ext.: 422
Fax: +9821 88795008